Steven J. Guillaudeu

Steven J. Guillaudeu

Auto-generated profile, based on publicly available information

Steven J. Guillaudeu

College of Chemistry, University of California, Berkeley, CA 94720-1460; and

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CLCameron C. Lee
Cameron C. Lee
Elizabeth GilliesElizabeth Gillies
Elizabeth Gillies
MFMegan E. Fox
Megan E. Fox
SGSteven J. Guillaudeu
Steven J. Guillaudeu
JFJean M. J. Fréchet
Jean M. J. Fréchet
FSFrancis C. Szoka
Francis C. Szoka
The antitumor effect of doxorubicin (DOX) conjugated to a biodegradable dendrimer was evaluated in mice bearing C-26 colon carcinomas. An asymmetric biodegradable polyester dendrimer containing 8–10 wt % DOX was prepared. The design of the dendrimer carrier optimized blood circulation time through size and molecular architecture, drug loading through multiple attachment sites, solubility through PEGylation, and drug release through the use of pH-sensitive hydrazone linkages. In culture, dendrimer–DOX was >10 times less toxic than free DOX toward C-26 colon carcinoma cells after exposure for 72 h. Upon i.v. administration to BALB/c mice with s.c. C-26 tumors, dendrimer–DOX was eliminated from the serum with a half-life of 16 ± 1 h, and its tumor uptake was ninefold higher than i.v. administered free DOX at 48 h. In efficacy studies performed with BALB/c mice bearing s.c. C-26 tumors, a single i.v. injection of dendrimer–DOX at 20 mg/kg DOX equivalents 8 days after tumor implantation caused complete tumor regression and 100% survival of the mice over the 60-day experiment. No cures were achieved in tumor-implanted mice treated with free DOX at its maximum tolerated dose (6 mg/kg), drug-free dendrimer, or dendrimer–DOX in which the DOX was attached by means of a stable carbamate bond. The antitumor effect of dendrimer–DOX was similar to that of an equimolar dose of liposomal DOX (Doxil). The remarkable antitumor activity of dendrimer–DOX results from the ability of the dendrimer to favorably modulate the pharmacokinetics of attached DOX.

30 September 2005 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
BHBrett Helms
Brett Helms
SGSteven J. Guillaudeu
Steven J. Guillaudeu
YXYu Xie
Yu Xie
MMMeredith McMurdo
Meredith McMurdo
CHCraig J. Hawker
Craig J. Hawker
JFJean M. J. Fréchet
Jean M. J. Fréchet

20 January 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AAAdah Almutairi
Adah Almutairi
RRRaffaella Rossin
Raffaella Rossin
MSMonica Shokeen
Monica Shokeen
AHAviv Hagooly
Aviv Hagooly
AAAshwin Ananth
Ashwin Ananth
JFJean M. J. Fréchet
Jean M. J. Fréchet
A biodegradable positron-emitting dendritic nanoprobe targeted at α v β 3 integrin, a biological marker known to modulate angiogenesis, was developed for the noninvasive imaging of angiogenesis. The nanoprobe has a modular multivalent core-shell architecture consisting of a biodegradable heterobifunctional dendritic core chemoselectively functionalized with heterobifunctional polyethylene oxide (PEO) chains that form a protective shell, which imparts biological stealth and dictates the pharmacokinetics. Each of the 8 branches of the dendritic core was functionalized for labeling with radiohalogens. Placement of radioactive moieties at the core was designed to prevent in vivo dehalogenation, a potential problem for radiohalogens in imaging and therapy. Targeting peptides of cyclic arginine–glycine–aspartic acid (RGD) motifs were installed at the terminal ends of the PEO chains to enhance their accessibility to α v β 3 integrin receptors. This nanoscale design enabled a 50-fold enhancement of the binding affinity to α v β 3 integrin receptors with respect to the monovalent RGD peptide alone, from 10.40 nM to 0.18 nM IC 50 . Cell-based assays of the 125 I-labeled dendritic nanoprobes using α v β 3 -positive cells showed a 6-fold increase in α v β 3 receptor-mediated endocytosis of the targeted nanoprobe compared with the nontargeted nanoprobe, whereas α v β 3 -negative cells showed no enhancement of cell uptake over time. In vivo biodistribution studies of 76 Br-labeled dendritic nanoprobes showed excellent bioavailability for the targeted and nontargeted nanoprobes. In vivo studies in a murine hindlimb ischemia model for angiogenesis revealed high specific accumulation of 76 Br-labeled dendritic nanoprobes targeted at α v β 3 integrins in angiogenic muscles, allowing highly selective imaging of this critically important process.

4 January 2008 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
SGSteven J. Guillaudeu
Steven J. Guillaudeu
MFMegan E. Fox
Megan E. Fox
YHYarah M. Haidar
Yarah M. Haidar
EDEdward E. Dy
Edward E. Dy
FSFrancis C. Szoka
Francis C. Szoka
JFJean M. J. Fréchet
Jean M. J. Fréchet

9 July 2009 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MFMegan E. Fox
Megan E. Fox
SGSteve Guillaudeu
Steve Guillaudeu
JFJean M. J. Fréchet
Jean M. J. Fréchet
KJKatherine Jerger
Katherine Jerger
NMNichole Macaraeg
Nichole Macaraeg
FSFrancis C. Szoka
Francis C. Szoka

19 December 2007 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AAAdah Almutairi
Adah Almutairi
SGSteven J. Guillaudeu
Steven J. Guillaudeu
MBMikhail Y. Berezin
Mikhail Y. Berezin
Samuel AchilefuSamuel Achilefu
Samuel Achilefu
JFJean M. J. Fréchet
Jean M. J. Fréchet